TitleDate
iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences MeetingMay 10, 2021
iCo Therapeutics Announces 2020 Year End Financial Results and Resignation of Susan KoppyMay 1, 2021
iCo Therapeutics Inc. Announces Closing of Upsized Subscription Receipt Private PlacementApril 28, 2021
iCo Therapeutics Inc. Announces Upsized Subscription Receipt Private PlacementApril 23, 2021
iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.March 22, 2021
iCo Therapeutics, Inc. announces agreement for in vivo testing of iCo- 019 on SARS-CoV-2March 15, 2021
iCo Therapeutics Inc. Announces Warrant ExercisesMarch 11, 2021
iCo Therapeutics Inc. Proposes to Re-Price WarrantsJanuary 11, 2021
iCo Therapeutics Announces Joint Development of iCo-019 with Skymount MedicalDecember 31, 2020
iCo Therapeutics Announces Third Quarter 2020 Financial ResultsNovember 24, 2020
iCo Therapeutics Announces Option GrantsOctober 26, 2020
iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 – November 3rd, 2020October 21, 2020
iCo Therapeutics Announces Second Quarter 2020 Financial ResultsAugust 31, 2020
iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases JournalJuly 30, 2020
iCo Therapeutics Announces First Quarter 2020 Financial ResultsJuly 13, 2020
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo-019) Results to be Presented at Prestigious American Pharmaceutical Sciences Meeting and Discussion UpdatesJune 22, 2020
iCo Therapeutics Inc. Announces Q1 Interim Filing UpdateMay 29, 2020
iCo Therapeutics Announces 2019 Year End Financial ResultsMay 19, 2020
iCo Therapeutics Inc. Announces Annual Filing UpdateApril 27, 2020
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of ResearchApril 15, 2020
iCo Therapeutics Announces Leadership ChangesMarch 9, 2020
iCo Therapeutics Successfully Concludes Phase 1b Clinical Study Announces Positive Primary End Point for Oral Amphotericin BFebruary 25, 2020
iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow UpFebruary 10, 2020
iCo Therapeutics Inc. Proposes to Re-Price WarrantsJanuary 11, 2020
iCo Therapeutics Announces Option GrantsJanuary 10, 2020